Processa Pharmaceuticals (PCSA) Current Leases (2019 - 2025)
Processa Pharmaceuticals' (PCSA) quarterly Current Leases came in at $25584.0 in Q2 2025, down 72.54% YoY from $93181.0 in Q2 2024, and down 48.48% on a QoQ basis from $49659.0 in Q1 2025.
Processa Pharmaceuticals (PCSA) Current Leases (2019 - 2025) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 7 years of Current Leases data on file, last reported at $25584.0 in Q2 2025.
- Quarterly Current Leases fell 72.54% year-over-year to $25584.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $25584.0 (down 72.54% YoY) and the FY2024 annual result came in at $73020.0, down 12.71% from the prior year.
- Current Leases declined to $25584.0 in Q2 2025, from $49659.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $97270.0 in Q1 2021 to a low of $5899.0 in Q3 2024.
- A 5-year average of $69492.5 and a median of $80031.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases jumped 208.41% — and 2024, when it tumbled 92.87%.
- Tracing PCSA's Current Leases over 5 years: stood at $71078.0 in 2021, then gained by 11.0% to $78896.0 in 2022, then advanced by 6.02% to $83649.0 in 2023, then dropped by 12.71% to $73020.0 in 2024, then plunged by 64.96% to $25584.0 in 2025.
- The last three Current Leases figures came in at $25584.0 (Q2 2025), $49659.0 (Q1 2025), and $73020.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | - |
| 10 | Processa Pharmaceuticals | 6.05 Mn | 6.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 25,584.00 |
| Mar 31, 2025 | 49,659.00 |
| Dec 31, 2024 | 73,020.00 |
| Sep 30, 2024 | 5,899.00 |
| Jun 30, 2024 | 93,181.00 |
| Mar 31, 2024 | 89,680.00 |
| Dec 31, 2023 | 83,649.00 |
| Sep 30, 2023 | 82,744.00 |
| Jun 30, 2023 | 81,890.00 |
| Mar 31, 2023 | 81,166.00 |
| Dec 31, 2022 | 78,896.00 |
| Sep 30, 2022 | 76,260.00 |
| Jun 30, 2022 | 26,552.00 |
| Mar 31, 2022 | 49,121.00 |
| Dec 31, 2021 | 71,078.00 |
| Sep 30, 2021 | 92,769.00 |
| Jun 30, 2021 | 92,447.00 |
| Mar 31, 2021 | 97,270.00 |
| Dec 31, 2020 | 87,200.00 |
| Sep 30, 2020 | 79,765.00 |